Merck, AZ, Roche, BMS work off grid for mix-and-match immuno-oncology
This article was originally published in Scrip
In the three months running up to the annual ASCO meeting in Chicago, Merck & Co, AstraZeneca, Roche and Bristol-Myers Squibb each announced deals with external companies designed to strengthen the clinical hands of their most advanced immune-oncology products (Table 1). Most are clinical trial collaborations putting a second-drug overlay on a checkpoint inhibition canvas.
You may also be interested in...
Doesn't every biopharma company have an immuno-oncology strategy these days? It certainly seems that way, considering the number of drug developers that are labeling their therapeutic candidates as immunotherapies regardless of whether the description truly fits their asset.
The slow drip of pharma industry earnings announcements that began on April 19 with Roche and Johnson & Johnson will turn into a veritable stream over the next couple of weeks. Scrip takes a look at expectations around some of the main firms due to report.
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.